Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuroimmunol ; 360: 577720, 2021 11 15.
Article in English | MEDLINE | ID: mdl-34543880

ABSTRACT

It is well documented that sporadic Alzheimer's disease (AD) is a multifactorial disease and considered to be a result of several pathological events, both in the periphery and in the brain. The role of the peripheral immune system in the etiology and/or progression of the disease is not fully understood yet, and the results in humans are contradictory so far. Several animal models of AD have been generated and thoroughly characterized to elucidate disease mechanisms and evaluate numerous therapeutic strategies in preclinical studies. In the present study, we carried out a longitudinal evaluation of blood lymphocytes from male and female 3xTg-AD mice to document important immunological abnormalities in the periphery. We documented the age-dependent decrease in the percentage of CD3+ and CD4+ lymphocytes and an increase in the percentage CD3+CD4-CD8- (DN T) cells in the blood of 3xTg-AD mice compared with non-transgenic animals. Severe splenomegaly was observed in 3xTg-AD mice in contrast to wild-type animals. Importantly, all these abnormalities in the peripheral immune system appeared earlier and were more pronounced in males compared with females of the same age, which may account for the shorter lifespan of male mice. We suggest that future research should include the measurement of CD3+ and DN T cells as a potential immunological marker of disease progression in AD patients.


Subject(s)
Aging/immunology , Alzheimer Disease/immunology , Lymphocyte Count , Sex Characteristics , T-Lymphocyte Subsets/immunology , Aging/blood , Alzheimer Disease/blood , Animals , CD3 Complex/analysis , CD4 Antigens/analysis , CD8 Antigens/analysis , Disease Models, Animal , Disease Progression , Female , Humans , Male , Mice , Mice, Transgenic , T-Lymphocyte Subsets/chemistry
2.
Inflammopharmacology ; 2017 May 19.
Article in English | MEDLINE | ID: mdl-28526927

ABSTRACT

It has been demonstrated that peripheral infections accompanied by neuroinflammation may modify brain development or affect normal brain aging and represent major risk factors for the development of neurological disorders. A wide range of synthetic and natural compounds with anti-inflammatory properties have been evaluated in animal models of neuroinflammation and neurodegeneration as an adjuvant therapeutic strategy. In the present study we have demonstrated for the first time that sodium thiosulphate (STS), a known antidote approved for treatment of certain medical conditions, is capable of reducing brain inflammation caused by systemic LPS administration. STS reduced brain levels of pro-inflammatory cytokine interleukin-1ß (IL-1ß), cyclooxygenase-2 (COX-2), ionized calcium binding adaptor molecule 1 (Iba-1) and 18 kDa translocator protein (TSPO) in an animal model of systemic LPS-induced neuroinflammation. In addition, we demonstrated for the first time elevated TSPO expression in retinal ganglion cells layer after peripheral LPS challenge and inhibition of ocular TSPO expression after treatment with STS. We think that STS may be used as an adjuvant anti-inflammatory therapy for many pathological conditions associated with inflammation in the brain.

3.
J Neuroimmunol ; 297: 20-7, 2016 08 15.
Article in English | MEDLINE | ID: mdl-27397072

ABSTRACT

Neuroinflammation is an important feature in the pathogenesis and progression of neurodegenerative diseases. Molecules with anti-inflammatory properties have been evaluated in animal models of neuroinflammation and neurodegeneration as an adjuvant therapeutic strategy. In the present study we have demonstrated that alpha-mangostin (α-MG), a natural xanthone purified from mangosteen pericarp, reduced brain levels of pro-inflammatory cytokine interleukin-6 (IL-6), cyclooxygenase-2 (COX-2) and 18 kDa translocator protein (TSPO) in an animal model of peripheral LPS-induced neuroinflammation. We think that evaluation of α-MG as an adjuvant treatment in preclinical models of AD, PD, multiple sclerosis and other diseases with known shared pathology merits further consideration.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Encephalitis/chemically induced , Encephalitis/drug therapy , Lipopolysaccharides/toxicity , Xanthones/therapeutic use , Analysis of Variance , Animals , Calcium-Binding Proteins/metabolism , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Disease Models, Animal , Encephalitis/pathology , Female , Gene Expression Regulation/drug effects , Glial Fibrillary Acidic Protein/metabolism , Mice , Mice, Inbred C57BL , Microfilament Proteins/metabolism , Microglia/drug effects , Receptors, GABA/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...